In a new editorial, Yale Cancer Center’s Patricia LoRusso, DO, Associate Cancer Center Director for Experimental Therapeutics and Director of the Phase I Clinical Trials Program at Smilow Cancer Hospital, reviews the first phase I study investigating the inhibitor Sotorasib for patients with advanced cancers found to have a KRAS G12C mutation. The review, “One Step at a Time — Clinical Evidence That KRAS Is Indeed Druggable," published today in the New England Journal of Medicine (NEJM).
“This study is very encouraging as patients with advanced stage tumors with KRAS mutations tend to have limited treatment options and poor outcomes,” said LoRusso. “After analyzing the data in this trial, including response rates and toxicity profiles, I am hopeful we are on our way to seeing many new targets drugged that were previously considered undruggable.”
In the reviewed study, also published in NEJM, findings resulted in manageable toxicities and durable clinical benefits for patients with KRAS G12C-mutant advanced cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer. Although results are early, it is the first KRAS inhibitor to show activity in any cancer.
The editorial can be viewed here: https://www.nejm.org/doi/full/10.1056/NEJMe2026372